Table 5 Subsequent systemic treatment and effectiveness.
Total (n = 24) | |
|---|---|
5-FU/cisplatin-based chemotherapy, n (%) | 18 (75.0) |
5-FU and cisplatin | 8 (33.3) |
5-FU, cisplatin and mitoxantrone | 12 (50.0) |
Oral MKIs, n (%) | 5 (20.8) |
Immune checkpoint inhibitors, n (%) | 5 (20.8) |
Disease control rate (%) | |
5-FU/cisplatin-based chemotherapy | 38.9 |
Oral MKIs | 20.0 |
Immune checkpoint inhibitors | 80.0 |
